secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000950170-24-025891
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q4 net loss narrows to $1.3M; achieves adj. EBITDA breakeven; reiterates FY2024 guidance
--------------------------------------------------------------------------------

- Q4 net loss attributable to Cerus narrowed to $1.3M ($0.01/share) from $13.6M ($0.08) a year ago.
- Q4 total revenue $53.3M (+4% YoY); product revenue $46.8M (+6% YoY), driven by North America platelet growth.
- Achieved Q4 adjusted EBITDA breakeven at +$4.7M vs -$3.7M in Q4 2022.
- Reiterated FY2024 product revenue guidance of $172-175M; INTERCEPT Fibrinogen Complex expected $8-10M.
- Cash and investments $65.9M at Dec 31; net cash used in ops $43.2M for FY2023, up from $25.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/0000950170-24-025891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000095017024025891/cers-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-025891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer